Table 1.
Phenolic compounds which show significant differences between their abundance in LigDFG transgenic Arabidopsis plants and wild type
| nr | m/z | RT (min) | Identity | WT | amyDFG10 | amyDFG12 | ppiDFG1 | Ratio of amyDFG10/WT |
|---|---|---|---|---|---|---|---|---|
| Compounds with increased abundance in amyDFG10 | ||||||||
| HPV‐like compounds | ||||||||
| 1 | 357.12 | 4.50 | HPV + hexose | 1569 | 8751 | 1502 | 2062 | 5.58 |
| 2 | 387.13 | 5.01 | HPS + hexose | 240 | 1944 | 187 | 196 | 8.10 |
| 3 | 399.16 | 6.45 | HPV + hexose + acetate | 2568 | 6277 | 2365 | 2000 | 2.44 |
| Dilignols and dilignol hexosides | ||||||||
| 4 | 373.13 | 11.85 | Gox(β‐O‐4)G | 1838 | 10 382 | 2079 | 2127 | 5.65 |
| 5 | 371.11 | 14.26 | Gox(β‐O‐4)G′ | 246 | 2020 | 132 | 405 | 8.21 |
| 6 | 581.19 | 8.42 | Gox(β‐O‐4)G 4‐O‐hexoside (formic acid adduct) | 28 | 2616 | 32 | 19 | 93.43 |
| Neolignan‐like compounds | ||||||||
| 7 | 549.16 | 8.68 | Gox(β‐O‐4)FA + hexose | 1126 | 8516 | 562 | 982 | 7.56 |
| 8 | 549.16 | 9.19 | Gox(β‐O‐4)FA + hexose | 5 | 1634 | 4 | 4 | 326.80 |
| 9 | 549.15 | 9.73 | Gox(β‐O‐4)FA + hexose | 470 | 4759 | 313 | 375 | 10.13 |
| 10 | 503.12 | 12.21 | Gox(β‐O‐4)FA + malate | 1218 | 11 972 | 1039 | 1351 | 9.83 |
| 11 | 503.12 | 12.85 | Gox(β‐O‐4)FA + malate | 639 | 6681 | 559 | 636 | 10.46 |
| 12 | 665.17 | 9.06 | Gox(β‐O‐4)FA + malate + hexose | 6 | 1358 | 7 | 0 | 226.33 |
| 13 | 665.17 | 9.21 | Gox(β‐O‐4)FA + malate + hexose | 354 | 6307 | 185 | 384 | 17.82 |
| 14 | 773.23 | 14.02 | Gox(β‐O‐4)FA + hexose + sinapic acid | 1897 | 21 354 | 2273 | 2520 | 11.26 |
| 15 | 773.23 | 15.36 | Gox(β‐O‐4)FA + hexose + sinapic acid | 43 | 5128 | 123 | 79 | 119.26 |
| 16 | 935.29 | 11.14 | Gox(β‐O‐4)FA + hexose + hexose + sinapic acid | 94 | 5794 | 114 | 244 | 61.64 |
| 17 | 935.29 | 11.24 | Gox(β‐O‐4)FA + hexose + hexose + SA | 63 | 4159 | 11 | 173 | 66.02 |
| 18 | 935.29 | 11.71 | Gox(β‐O‐4)FA + hexose + hexose + SA | 17 | 1982 | 0 | 75 | 116.59 |
| 19 | 516.15 | 10.13 | Gox(β‐O‐4)FA + glutamic acid | 17 | 1459 | 40 | 18 | 85.82 |
| 20 | 417.12 | 12.29 | Gox(β‐O‐4)SA + malate (‐malate) | 419 | 1620 | 320 | 382 | 3.87 |
| 21 | 417.12 | 13.22 | Gox(β‐O‐4)SA + malate (‐malate) | 218 | 1367 | 193 | 181 | 6.27 |
| Compounds with unknown identity | ||||||||
| 22 | 225.04 | 3.47 | Unknown | 393 | 1010 | 333 | 417 | 2.57 |
| 23 | 385.12 | 12.17 | Unknown | 49 607 | 86 594 | 43 207 | 55 871 | 1.75 |
| 24 | 387.15 | 8.74 | Unknown | 2275 | 6362 | 2198 | 2226 | 2.80 |
| Compounds with decreased abundance in amyDFG10 | ||||||||
| Compounds with unknown identity | ||||||||
| 25 | 419.14 | 8.57 | Unknown | 1583 | 394 | 1319 | 1264 | 0.25 |
| 26 | 389.13 | 8.88 | Unknown | 4931 | 1970 | 3762 | 3823 | 0.40 |
All significant differences in abundance were observed between the amyDFG10 line and wild type. The ratio represents the fold‐change in abundance between the listed transgenic line as compared to wild type. s.d., standard deviation; HPV, hydroxypropiovanillone; HPS, hydroxypropiosyringone; G, guaiacyl unit; Gox, α‐keto‐oxidized guaiacyl unit. The chemical structures of compounds 1–21 are shown in Figure 6.